Analyst Gil Blum from Needham maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) and keeping the price target at $42.00.
Gil Blum has given his Buy rating due to a combination of factors related to Rocket Pharmaceuticals’ ongoing clinical developments and financial stability. The company is progressing with its pivotal study on RP-A501 for Danon disease, with topline results anticipated in mid-2026, which suggests potential for significant advancement in their pipeline.
Additionally, Rocket Pharmaceuticals has a solid financial position, ending the first quarter of 2025 with $318 million, which extends their cash runway guidance into the fourth quarter of 2026. This financial stability, combined with the expected resolution of regulatory challenges and the finalization of a BLA submission for RP-L102, supports the positive outlook and the Buy rating.
In another report released today, J.P. Morgan also maintained a Buy rating on the stock with a $44.00 price target.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.